The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis.

Fatty liver disease, also called metabolic dysfunction-associated steatohepatitis (MASH), is a condition where fat ...

Ozempic, a diabetes drug, shows promise for liver disease. Research indicates it can reverse non-alcoholic steatohepatitis. A ...

Scientists are continuing to find evidence that GLP-1 medications can temper cravings for alcohol and other drugs.

Chances are, you haven’t heard of metabolic dysfunction–associated steatohepatitis (MASH)—but you’ve almost definitely heard ...

Understand how semaglutide shows strong benefits in MASH treatment, improving liver health and reducing weight.

Should everyone with liver disease be on Ozempic? Not so fast. While this is exciting news, semaglutide isn’t approved yet specifically for NASH or fatty liver disease—it’s currently ...

Once hailed primarily as a diabetes drug and later catapulted into stardom for its weight-loss benefits, Ozempic (semaglutide ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be ...

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...